FLNA FILANA THERAPEUTICS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1069530 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY60.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-60.5%
ROA-36.7%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets42.1%
Debt / equity0.00x
Current ratio1.91x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.68x
Accruals ratio-11.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $3.87M | $3.30M | $4.54M | $3.85M | $3.96M | $5.12M | $13.67M | $20.53M |
| SG&A expense | $7.41M | $6.09M | $6.62M | $9.70M | $7.91M | $40.28M | $10.92M | $8.96M |
| Operating income | -$11.27M | -$9.39M | -$11.17M | -$13.55M | -$11.86M | -$45.39M | -$24.59M | -$29.49M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$10.73M | -$8.60M | -$10.33M | -$12.54M | -$10.81M | -$44.22M | -$23.40M | -$27.60M |
| EBITDA | -$11.07M | -$9.09M | -$10.93M | -$13.22M | -$11.66M | -$45.19M | -$24.37M | -$29.26M |
| EPS (basic) | -0.22 | -0.18 | -0.21 | — | -0.22 | -0.92 | -0.48 | — |
| EPS (diluted) | — | — | — | — | -0.22 | -0.92 | -0.48 | — |
| Weighted avg. shares (diluted) | — | — | — | — | 48.31M | 48.31M | 48.26M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $46.99M | $82.68M | $86.57M | $95.50M | $106.08M | $112.38M | $117.33M | $128.57M |
| Current assets | $80.06M | $83.72M | $87.96M | $97.71M | $108.91M | $114.82M | $120.15M | $136.53M |
| PP&E, net | $20.00M | $20.18M | $20.40M | $20.65M | $20.82M | $20.56M | $20.78M | $21.00M |
| Intangibles | — | — | — | $193,000 | — | — | — | $37,000 |
| Total assets | $100.06M | $103.90M | $108.37M | $118.36M | $129.73M | $135.38M | $140.93M | $157.53M |
| Current liabilities | $41.95M | $40.16M | $40.12M | $43.83M | $48.05M | $47.33M | $13.24M | $11.75M |
| Total liabilities | $42.08M | $40.29M | $40.23M | $43.95M | $48.16M | $47.41M | $13.32M | $11.83M |
| Shareholders' equity | $57.98M | $63.61M | $68.14M | $74.40M | $81.57M | $87.97M | $127.62M | $145.70M |
| Shares outstanding | 50.07M | 48.31M | 48.31M | 48.31M | 48.31M | 48.31M | 48.31M | 48.20M |
| Cash flow statement | ||||||||
| Operating cash flow | -$6.09M | -$3.85M | -$8.88M | -$9.75M | -$6.22M | -$4.95M | -$11.34M | -$61.27M |
| Capital expenditure | $31,000 | — | — | $501,000 | $80,000 | $0 | $0 | $57,000 |
| Free cash flow | -$6.12M | — | — | -$10.25M | -$6.30M | -$4.95M | -$11.34M | -$61.32M |
| Investing cash flow | -$31,000 | — | — | -$501,000 | -$80,000 | $0 | $0 | -$57,000 |
| Financing cash flow | $1.68M | -$16,000 | -$51,000 | -$329,000 | $0 | $0 | $90,000 | $918,000 |
| Depreciation & amortization | $200,000 | $300,000 | $243,000 | $334,000 | $200,000 | $200,000 | $220,000 | $228,000 |
| Stock-based compensation | $3.48M | $4.07M | $4.07M | $5.37M | $4.40M | $4.58M | $5.22M | $5.74M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.